NCT02273219View on ClinicalTrials.gov

Trial of AEB071 in Combination With BYL719 in Patients With Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 19, 2014

Primary Completion Date

October 18, 2017

Study Completion Date

July 2, 2018

Conditions
Uveal Melanoma
Interventions
DRUG

AEB071

Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)

DRUG

BYL719

Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds

Trial Locations (3)

10032

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering Cancer Center, New York

33136

Bascom Palmer Eye Institute of University Of Miami Medical Center, Miami

All Listed Sponsors
lead

Columbia University

OTHER

NCT02273219 - Trial of AEB071 in Combination With BYL719 in Patients With Melanoma | Biotech Hunter | Biotech Hunter